Boston Scientific (BSX) PT Raised to $53 at Cowen

Cowen analyst Joshua Jennings raised the price target on Boston Scientific (NYSE: BSX) to $53.00 (from $47.00) while maintaining an Outperform rating.

The analyst commented, "BSX posted 2Q revenue and EPS of $3.08B and $0.40, beating Street estimates of $2.94B and $0.37. Organic sales growth was 9% compared to 2Q'19. Management raised its full-year revenue and EPS outlook and issued 3Q guidance that, on its lower end, overlaps the current consensus forecasts. We believe BSX remains on track to return to its pre-pandemic norms by year-end. Increasing PT to $53 from $47."

You May Also Be Interested In

• Bernstein SocGen Group Upgrades Analog Devices (ADI) to Outperform
• Home Depot (HD) PT Raised to $373 at Truist Securities
• Bally's Corp (BALY) PT Lowered to $10; Truist Securities: 'Mixed results amidst a "going concern"'